UNSPSC 51102877: Ambroxol/clarithromycin

This classification denotes a combination drug composed of two constituents: a mucolytic and a macrolide antibiotic, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90].

UNSPSC 51102877 Ambroxol/clarithromycin, a Commodity code, covers pharmaceutical products and related medical supplies that state and local governments procure for health departments, emergency response agencies, and public health initiatives. Recent solicitations under this code show state and local buyers acquiring naloxone and drug deactivation systems, medical and first aid supplies for emergency responders, and generic multi-source pharmaceuticals through cooperative purchasing agreements. The issuing bodies include county health departments, city fire departments, state health agencies, and multistate cooperative purchasing alliances. Work centers on procuring finished pharmaceuticals, emergency medical supplies, and OTC products with compliance requirements including FDA certification, cGMP and Drug Supply Chain Security Act adherence, appropriate insurance coverage, and expiration-date minimums ranging from six months to nine months from delivery or manufacture.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released an IFB (60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to a county health facility, due July 26, 2023. The City of Tampa issued an IFB (26P00145) in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a $700,000 estimated value and SLBE sheltered-market designation, due March 13, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling future formal procurement activity around pharmacy benefit management and direct contracting models.